Distribution of calcitonin gene-related peptide-like immunoreactivity in the brain of the small-spotted dogfish,scyliorhinus canicula L

1995 ◽  
Vol 352 (3) ◽  
pp. 335-350 ◽  
Author(s):  
Pilar Molist ◽  
Isabel Rodriguez-Moldes ◽  
Trevor F. C. Batten ◽  
Ramon Anadon
2002 ◽  
Vol 447 (2) ◽  
pp. 99-113 ◽  
Author(s):  
Fernando Martínez-García ◽  
Amparo Novejarque ◽  
José M. Landete ◽  
Jose Moncho-Bogani ◽  
Enrique Lanuza

Author(s):  
Ann C. Raddant ◽  
Andrew F. Russo

Over the past two decades, a convergence of basic and clinical evidence has established the neuropeptide calcitonin-gene-related peptide (CGRP) as a key player in migraine. Although CGRP is a recognised neuromodulator of nociception, its mechanism of action in migraine remains elusive. In this review, we present evidence that led us to propose that CGRP is well poised to enhance neurotransmission in migraine by both peripheral and central mechanisms. In the periphery, it is thought that local release of CGRP from the nerve endings of meningeal nociceptors following their initial activation by cortical spreading depression is critical for the induction of vasodilation, plasma protein extravasation, neurogenic inflammation and the consequential sensitisation of meningeal nociceptors. Mechanistically, we propose that CGRP release can give rise to a positive-feedback loop involved in localised increased synthesis and release of CGRP from neurons and a CGRP-like peptide called procalcitonin from trigeminal ganglion glia. Within the brain, the wide distribution of CGRP and CGRP receptors provides numerous possible targets for CGRP to act as a neuromodulator.


1992 ◽  
Vol 657 (1 Calcitonin Ge) ◽  
pp. 119-134 ◽  
Author(s):  
TOMAS HÖKFELT ◽  
ULF ARVIDSSON ◽  
SANDRA CECCATELLI ◽  
ROSER CORTÉS ◽  
STAFFAN CULLHEIM ◽  
...  

Pharmacology ◽  
2019 ◽  
Vol 104 (5-6) ◽  
pp. 332-341 ◽  
Author(s):  
Karin Warfvinge ◽  
Lars Edvinsson ◽  
Darryl S. Pickering ◽  
Majid Sheykhzade

Aim: The aim of present study is to investigate the binding characteristics of non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists (i.e., gepants) in the brain membranes of rat, pig and human. Methods: The interaction of available gepants with the CGRP receptor was studied in the brain membranes of 3 different species using a radioligand competitive binding assay. In addition, the distribution of CGRP and its receptor component receptor activity modifying protein 1 (RAMP1) in rat cerebellum and cortex was explored using immunohistochemistry. Results: All gepants, except SB268262, displaced 100% of the radioligand specific binding in the brain tissue of all 3 species and showed highest affinity for CGRP receptors in human brain as compared to rat and pig brain membranes. Furthermore, radioligand binding studies revealed the presence of higher CGRP receptor density in human cerebellum compared to human cortex. The morphology, size and density of CGRP immunoreactive cells suggest that all cerebral cortical neurons were positive for CGRP. Slender receptor immunoreactive fibres were found spanning through the entire cortex. CGRP immunoreactivity was displayed in the cell soma of cerebellar Purkinje cells and in large neurons in the medial cerebellar nucleus. RAMP1 was found on the surface of the Purkinje cells and in parallel fibres, indicating presence in the granule cell axons. Conclusion: Cerebellum and cerebral cortex are rich in CGRP and CGRP receptors, which can be antagonized by gepants. However, all gepants display higher affinity for human CGRP receptors as compared to rat and pig CGRP receptors. Furthermore, human cerebellum seems to express higher density of CGRP receptors.


Cephalalgia ◽  
2019 ◽  
Vol 40 (3) ◽  
pp. 229-240 ◽  
Author(s):  
Rodrigo Noseda ◽  
Aaron J Schain ◽  
Agustin Melo-Carrillo ◽  
Jason Tien ◽  
Jennifer Stratton ◽  
...  

Background The presence of calcitonin gene-related peptide and its receptors in multiple brain areas and peripheral tissues previously implicated in migraine initiation and its many associated symptoms raises the possibility that humanized monoclonal anti-calcitonin gene-related peptide antibodies (CGRP-mAbs) can prevent migraine by modulating neuronal behavior inside and outside the brain. Critical to our ability to conduct a fair discussion over the mechanisms of action of CGRP-mAbs in migraine prevention is data generation that determines which of the many possible peripheral and central sites are accessible to these antibodies – a question raised frequently due to their large size. Material and methods Rats with uncompromised and compromised blood-brain barrier (BBB) were injected with Alexa Fluor 594-conjugated fremanezumab (Frema594), sacrificed 4 h or 7 d later, and relevant tissues were examined for the presence of Frema594. Results In rats with uncompromised BBB, Frema594 was similarly observed at 4 h and 7 d in the dura, dural blood vessels, trigeminal ganglion, C2 dorsal root ganglion, the parasympathetic sphenopalatine ganglion and the sympathetic superior cervical ganglion but not in the spinal trigeminal nucleus, thalamus, hypothalamus or cortex. In rats with compromised BBB, Frema594 was detected in the cortex (100 µm surrounding the compromised BBB site) 4 h but not 7 d after injections. Discussion Our inability to detect fluorescent (CGRP-mAbs) in the brain supports the conclusion that CGRP-mAbs prevent the headache phase of migraine by acting mostly, if not exclusively, outside the brain as the amount of CGRP-mAbs that enters the brain (if any) is too small to be physiologically meaningful.


1992 ◽  
Vol 657 (1 Calcitonin Ge) ◽  
pp. 164-169 ◽  
Author(s):  
A. SARIA ◽  
G. BERNATZKY ◽  
C. HUMPEL ◽  
C. HARING ◽  
G. SKOFITSCH ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Joanna Zajdel ◽  
Johan Sköld ◽  
Maarit Jaarola ◽  
Anand Kumar Singh ◽  
David Engblom

AbstractCalcitonin gene related peptide (CGRP) expressing neurons in the parabrachial nucleus have been shown to encode danger. Through projections to the amygdala and other forebrain structures, they regulate food intake and trigger adaptive behaviors in response to threats like inflammation, intoxication, tumors and pain. Despite the fact that this danger-encoding neuronal population has been defined based on its CGRP expression, it is not clear if CGRP is critical for its function. It is also not clear if CGRP in other neuronal structures is involved in danger-encoding. To examine the role of CGRP in danger-related motivational responses, we used male and female mice lacking αCGRP, which is the main form of CGRP in the brain. These mice had no, or only very weak, CGRP expression. Despite this, they did not behave differently compared to wildtype mice when they were tested for a battery of danger-related responses known to be mediated by CGRP neurons in the parabrachial nucleus. Mice lacking αCGRP and wildtype mice showed similar inflammation-induced anorexia, conditioned taste aversion, aversion to thermal pain and pain-induced escape behavior, although it should be pointed out that the study was not powered to detect any possible differences that were minor or sex-specific. Collectively, our findings suggest that αCGRP is not necessary for many threat-related responses, including some that are known to be mediated by CGRP neurons in the parabrachial nucleus.


Sign in / Sign up

Export Citation Format

Share Document